Home > Insider Trading > Filing (0001140361-16-053978)

Filing Details

Accession Number:: 0001140361-16-053978
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-02-18 17:50:25
Reporting Period:: 2016-02-10

Filing Date:: 2016-02-18
Accepted Time:: 2016-02-18 17:50:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1445283	Proteostasis Therapeutics Inc.	PTI	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
737186	Perrigo Corp Ltd.	Treasury Building, Lower Grand Canal St Dublin 2 L2 2	No	No	Yes	No
1307004	Ltd. International Pharma Elan	Treasury Building, Lower Grand Canal Street Dublin L2 2	No	No	Yes	No
1323996	Ltd. Holdings Perrigo	Treasury Building, Lower Grand Canal Street Dublin L2 2	No	No	Yes	No
1565579	Ltd. One Science Perrigo	Treasury Building, Lower Grand Canal Street Dublin L2 2	No	No	Yes	No
1585364	Perrigo Co Plc	Treasury Building Lower Grand Canal Street Dublin L2 2	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-02-17	2,416,612	$0.00	2,416,612	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-02-17	366,455	$0.00	2,783,067	No	4	C	Indirect	See footnote
Common Strock	Acquisiton	2016-02-17	125,000	$8.00	2,908,067	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Redeemable Preferred Stock	Disposition	2016-02-17	20,000,000	$0.00	2,416,612	$0.00
Common Stock	Series B Convertible Redeemable Preferred Stock	Disposition	2016-02-17	3,961,459	$0.00	366,455	$0.00
Common Stock	Stock Option (Right to Buy)	Acquisiton	2016-02-10	45,760	$0.00	45,760	$8.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
45,760	2016-02-10	No	4	A	Indirect

Footnotes

The Series A Convertible Redeemable Preferred Stock (the "Series A Shares") automatically converted on a 10.8102-to-1 basis into the Issuer's Common Stock, together with the accrued but unpaid dividends, upon closing of the Issuer's initial public offering into 2,416,612 shares of the Issuer's Common Stock. The Series A Shares did not have an expiration date.
The Series B Convertible Redeemable Preferred Stock (the "Series B Shares") automatically converted on a 10.8102-to-1 basis into the Issuer's Common Stock upon closing of the Issuer's initial public offering into 366,455 shares of the Issuer's Common Stock. The Series B Shares did not have an expiration date.
Perrigo Science One Ltd. ("Science") (formerly Elan Science One Ltd.) is the direct owner of these securities. Science is a direct or indirect, wholly-owned subsidiary of each of the other reporting persons.
These securities were purchased in connection with the initial public offering of the Issuer.
These securities shall vest and become exercisable in equal quarterly installments starting on February 10, 2016 until the option is fully vested and exercisable on February 10, 2019, subject to continued service.
Perrigo Company plc ("Perrigo") and the other reporting persons named herein may be deemed to beneficially own the 45,760 options granted to Mr. Walshe in his capacity as a director of Proteostasis Therapeutics, Inc. (the "Company"). Mr. Walshe has an understanding with Perrigo pursuant to which he holds such securities for the benefit of Perrigo.